Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Shows Grace Under Pressure From Biosimilars And Other Threats

Executive Summary

Oncology stars Darzalex and Imbruvica lift a strong fourth quarter, but Remicade biosimilars and pricing discounts continue to threaten to take a bite out of future performance. Tax reform and Amazon's potential entry into healthcare could also affect the diversified firm.

Advertisement

Related Content

Pfizer, Astellas Accelerate Xtandi's Timeline In Early Prostate Cancer
How Is Pharma Spending Tax Savings? Not On Drug Pricing, Sen. Booker Says
J&J Stays Within Price Pledge, But Average Doesn't Tell The Whole Story, Analyst Says
J&J's Apalutamide, Astellas/Pfizer's Xtandi On Par For Non-Metastatic Prostate Cancer
Mysterious Amazon/Berkshire/JPMorgan Partnership Could Disrupt Health Care, Pharma
PTAB Clears Path For Earlier Generic Zytiga Launch
Express Scripts CEO: “I Don’t Mind If Amazon Comes In”
Payers Like Biosimilars, But Rebates Remain The Bottom Line (For Now)
Amazon-Express Scripts Partnership? PBM Sees Opportunity In Uninsured Market
J&J Immunology Growth Now Hinges On Stelara, Tremfya After RA Setback

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100256

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel